Cyclandelate

DB04838ApprovedWithdrawnSmall molecule

Cyclandelate is a vasodilator used for the treatment of various blood vessel diseases, such as claudication and arteriosclerosis. A direct-acting smooth muscle relaxant used to dilate blood vessels.

Mechanism: Cyclandelate produces peripheral vasodilation by a direct effect on vascular smooth muscle. Pharmacological action may be due to calcium-channel antagonism.
Curator reviewed
Primary indication: Used in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps.Curator reviewed
Formula / weight: C₁₇H₂₄O₃ · 276.3707 g/mol (avg)
First approval: Canada, 1994

Resolves to

Compound

UNII4139O1OAY2CAS456-59-7ChEMBLCHEMBL1480987ChEBI3988PubChem2893

Clinical / RWD

RxNorm2970ATCC04AX01PharmGKBPA164748026

Structure

InChIKeyWZHCOOQXZCIUNC-UHFFFAOYSA-NSMILESCC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1

Targets

P54289CACNA2D1P23141CES1

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

770Drug interactionsStructured to mechanism, not free text

2Marketed productsAcross 2 countries and 2 labellers

1ATC codeIncluding every combination product, plus 13 drug categories

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cyclandelate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In